Frederick L. Locke, MD
Chicago—In patients with refractory diffuse large B-cell lymphoma (DLBCL), response rates with axicabtagene ciloleucel (axi-cel) were only slightly lower after four or more lines of prior therapy than after fewer lines, according to an analysis from a pivotal phase 2 trial.
These results and a second analysis showing deepening rates of response over time indicate a considerable rate of activity with this anti-CD19 chimeric antigen receptor (CAR) T-cell